Beijing QL Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Beijing QL Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Kidney patients get first look at new obesity drug Results expected Dec 2026 (estimated)
- New obesity drug ZT002 tested for safety with other medications Results expected Dec 2026 (estimated)
- New Weight-Loss pill ZT006 enters Mid-Stage trial Results expected Dec 2026 (estimated)
- New drug ZT003 tested for safety in first human trial Results expected Dec 2026 (estimated)
- Heart safety check for new Weight-Loss drug candidate Results expected Jan 2027 (estimated)
-
New Weight-Loss drug zovaglutide enters final testing phase
Disease control OngoingThis Phase 3 trial tests whether zovaglutide, given as a shot every 4 weeks, helps people with overweight or obesity lose weight. About 744 adults will receive either the drug or a placebo for 52 weeks. The study measures how much weight they lose and how many achieve at least 5%…
Phase 3 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New Weight-Loss pill ZT006 enters Mid-Stage trial
Disease control OngoingThis Phase 2 study tests whether ZT006, a daily or weekly tablet, helps overweight and obese adults lose weight when combined with diet and exercise. About 184 participants will receive either ZT006 or a placebo for 28 weeks, with some continuing for an extra 12 weeks. The main g…
Phase 2 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC